In this issue:
Dupilumab in adolescents with moderate-to-severe AD
Predicting response to omalizumab in chronic spontaneous urticaria
Long-term ixekizumab in psoriasis
Dupilumab + low-dose systemic steroids for bullous pemphigoid
Patient-reported outcomes in psoriasis treated with secukinumab
Abrocitinib switching from dupilumab in AD
Cost-utility of rituximab vs mycophenolate mofetil for pemphigus vulgaris
Response durability after abrocitinib discontinuation in AD
Risankizumab for plaque psoriasis in Russian patients
Plaque psoriasis treatment response time with anti-IL-17/23 biologics
Platelet-rich plasma monotherapies for androgenetic alopecia
Tildrakizumab for psoriasis in a real-world cohort
Please login below to download this issue (PDF)